CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 77 enrolled
Drug / intervention
Bromfenac Sodium 0.07% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07090044
NCT07090044Phase 4Completed

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

Retina Research Institute, LLC·interventional·Posted Jul 29, 2025·Updated Jul 29, 2025

In Brief

A Phase 4 clinical trial evaluating Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, and 1 other intervention for Vein Occlusion and 3 related conditions. Completed, enrolled 77 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain. The main questions it aims to answer are: \- Do bromfenac sodium and/or loteprednol etabonate improve post-injection pain scores compared to preservative-free artificial tears? Participants will: * Receive one drop of the topical drops five minutes prior to their regularly scheduled intravitreal injection. Depending on the treatment arm, they will also administer drops on their own at home up to 3 times per day on the day of their procedure. * They will answer a standardized pain score survey at 4 hours and 24 hours following their intravitreal injection and convey their results to study coordinators by phone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedJul 29, 2025
Enrollment StartAug 20, 2021
Primary CompletionDec 7, 2022
Study CompletionDec 8, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11 months ago

Interventions

Bromfenac Sodium 0.07%drug

Bromfenac sodium 0.07% is a nonsteroidal anti-inflammatory drug to be administered as one topical drop, one time 5 minutes prior to the regularly scheduled standard of care intravitreal injection.

Loteprednol Etabonate 0.38% Ophthalmic Gel/Jellydrug

Loteprednol etabonate 0.38% ophthalmic gel is a steroidal drug to be administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.

Propylene Glycol Preservative-free Artificial Tearsdrug

Propylene Glycol Preservative-free Artificial Tears is a placebo compartor administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.